Product Information
GALLIFREY 5 MG TABLET is a generic product labeled by Xiromed LLC, priced at $0.2898 per EA under NDC 70700032650. Its NADAC has been published 76 times since Apr 23, 2025.
FDA first approved this application on Nov 10, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Xiromed LLCNDC
70700032650
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NORETHINDRONE ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA205278FDA Approved
11/10/2016
TE Code
AB
On Market Since
9/6/2024
Pharmacological Classes
Price Statistics
The NADAC for GALLIFREY 5 MG TABLET has been published 76 times since Apr 23, 2025, and over the history we have for it it has declined 8.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2898 per EA |
|---|---|
| All-time high | $0.3150 (May 14, 2025) |
| All-time low | $0.2895 (Mar 18, 2026) |
| 52-week high | $0.3028 |
| 52-week low | $0.2895 |
| Median price | $0.2990 |
| Average price | $0.3013 |
| Largest weekly change | -3.4% (Sep 17, 2025) |
| Weeks tracked | 76 |
| Tracking since | Apr 23, 2025 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xiromed LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norethindrone Acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Progestin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GALLIFREY 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GALLIFREY 5 MG TABLET, manufactured by Xiromed LLC, is $0.2898 per EA (NDC 70700032650), effective Sep 30, 2026.
How has the price of GALLIFREY 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for GALLIFREY 5 MG TABLET has declined 8.0%. It has been tracked across 76 weekly CMS publications since Apr 23, 2025.
What are the highest and lowest recorded NADAC prices for GALLIFREY 5 MG TABLET?
Since Apr 23, 2025, the NADAC for GALLIFREY 5 MG TABLET has ranged from a low of $0.2895 (Mar 18, 2026) to a high of $0.3150 (May 14, 2025), with a median of $0.2990 per EA.
Are there cheaper alternatives to GALLIFREY 5 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GALLIFREY 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures GALLIFREY 5 MG TABLET?
GALLIFREY 5 MG TABLET (NDC 70700032650) is labeled by Xiromed LLC, and CMS classifies it as a generic product.